January 19, 2026
Landing Med has been selected for the World Economic Forum’s MINDS (Meaningful, Inclusive, and Novel Data Solutions) 2nd cohort, becoming the only pathology-focused company recognized for its impact in advancing health equity through the world’s first population-based AI-assisted cervical cytology screening program.
The company is honored for its work in scaling cervical cytology screening in underserved and rural communities using its AI-powered system and digital pathology tools. Leveraging AI, Landing Med has screened more than 13 million women, primarily in rural regions, significantly expanding access to early detection. These innovations also enable laboratories to adopt telepathology and digital workflows, improving access to timely and accurate diagnostics.
“We are deeply honored to be selected for the World Economic Forum’s MINDS cohort,” said Lan Wang, Head of Global Marketing. “This recognition highlights the importance of expanding access to cervical cytology screening and reinforces our commitment to health equity through innovation.”
Participation in the MINDS cohort will allow Landing Med to collaborate with global leaders, share best practices, and further expand access to high-quality screening services worldwide.
Read the report here: https://lnkd.in/eA_b4V5y
Read the press release here: https://lnkd.in/eKxiw6Ya
Find out more about the 2nd Cohort of MINDS: https://lnkd.in/ekEesaQd
fr 
es 
CN
